Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor Copanlisib Given in Combination With the Immunotherapeutic Agents Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

STATUS

Recruiting
End date

Jun 5, 2026
participants needed

35
sponsor

Big Ten Cancer Research Consortium

Send

Updated on 19 February 2024

See if I qualify

psychiatric disorder

HIV Infection

pulmonary disease

corticosteroids

hba1c

nivolumab

vasectomy

hormone therapy

endocrine therapy

autograft

heart failure

pneumonia

prednisone

rituximab

immunosuppressive agents

cell transplantation

lymphoma

flow cytometry

immunohistochemistry

copanlisib

hepatitis b surface antigen

arrhythmia

hepatitis

replacement therapy

crohn's disease

psoriasis

hypothyroidism

unstable angina

angina pectoris

marginal zone lymphoma

cirrhosis

pd-l1

cytotoxic chemotherapy

cyp3a4 inducers

angina

stem cell transplant

cardiac arrhythmia

vitiligo

investigational treatment

hepatitis c

interstitial lung disease

cyp3a4 inhibitors

indolent lymphoma

hormone replacement

attenuated vaccines

autologous stem cell transplantation

alcoholic cirrhosis

pi3k inhibitor

12 lead electrocardiogram

thyroiditis

central nervous system disease

ulcerative

autologous hematopoietic stem cell transplant

symptomatic congestive heart failure

hair thinning

hashimoto syndrome

malt

Summary

Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive

Copanlisib IV: day 1, 8, 15 every 28 days
Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only
Rituximab IV: Cycle 1 days 1, 8, 15, 22; then day 1 (C2-6); then Q2 cycles (8-12)

Description

Patients with relapsed/refractory lymphoma generally have few if any curative options and demonstrate poor response rates to standard salvage therapies. Novel regimens utilizing molecular targets are needed to improve outcomes in this patient population. While studies evaluating single agent small-molecule inhibitors have demonstrated activity in this setting, combinations of these drugs are generally thought to be more efficacious due to targeting separate mechanisms of action and decreased chance of developing resistance. The PD-1/PD-L1 axis is a molecular target that has been demonstrated to be up-regulated in several tumors including malignant lymphoma. Several pre-clinical studies have demonstrated the importance of this axis on clinical outcomes of patients afflicted with low grade lymphoma including FL. Targeting this axis with specific inhibitors would appear to be a rationale way to improve outcomes in patients afflicted with these diseases. PI3K inhibitors in addition to inhibiting signaling, impart changes in the immune cells in the tumor microenvironment and would appear to be a logical candidate to explore in combination with immunotherapy. Based on these preliminary data, we believe that we have justification for proceeding with our proposed phase I study to combine the PD-1 inhibitor, nivolumab, with the PI3K inhibitor, copanlisib, and the CD20 antibody, rituximab, in patients with relapsed/refractory follicular and marginal zone lymphoma. This work has the potential to provide a novel strategy to improve upon the clinical response noted in this patient population.

Details

Condition	Indolent Lymphoma
Age	18years - 100years
Treatment	Rituximab, Nivolumab, Copanlisib
Clinical Study Identifier	NCT04431635
Sponsor	Big Ten Cancer Research Consortium
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Age 18 years at the time of informed consent
	Diagnosis of relapsed or refractory indolent follicular or marginal zone lymphoma established by histologic assessment by a hematopathologist that has relapsed after at least one line of chemo-immunotherapy
	Immunohistochemistry of the biopsy or
	Flow cytometry of the biopsy
	ECOG Performance Status 2
	Has an indication for treatment based on the presence of symptoms and/or GELF criteria as referenced in appendix A
	Must have failed or not be a candidate for an autologous stem cell transplantation
	Women of childbearing potential must be willing to use appropriate contraception (barrier and hormonal therapy) or abstain from heterosexual activity from the point of registration through at least 12 months after the last dose of study drugs
	\-- NOTE: Women of childbearing potential are those who have not been
	surgically sterilized, have not been free of menses for 1 year, or her sole
	male partner has had a vasectomy at least 6 months prior to screening
	Male subjects capable of fathering a child must agree to use appropriate method(s) of contraception or abstain from heterosexual activity starting with the first dose of study drug through 7 months after the last dose of the study drugs
	Adequate organ function defined as
	Hepatic
	Total Bilirubin 1.5 mg/dL
	AST and ALT 2.5 x ULN
	Renal: Creatinine < 2.0 mg/dl or CrCL > 30 mL/minute
	Bone marrow function
	ANC 1000/mm3 (500/mm3 if known bone marrow (BM) involvement)
	Platelet 75,000/mm3 (or 50,000/mm3 if known BM involvement)
	Hgb > 9 g/dL (transfusions allowed to meet this criterion)
	Adequate glycemic control as demonstrated by a baseline fasting blood sugar (BS) 150 mg/dL. If uncontrolled then patient must be referred to PCP or endocrinology for medical management. Patient may be enrolled if adequate control is obtained prior to day 1 of therapy
	Adequate blood pressure (BP) control as demonstrated by a baseline BP of < 150/90. If uncontrolled then patient must be referred to PCP for medical management. Patient may be enrolled if adequate control is obtained prior to day 1 of therapy
	Prior treatment is allowed if
	at least 4 weeks must have elapsed since last chemotherapy and/or radiation and the patient has recovered to grade 1 toxicity from all treatment related events
	at least 3 months must have passed since radio-immunotherapy
	at least 3 months have passed since date of stem cell infusion (autograft) and patient has recovered to grade 1 toxicities related to this procedure
	Prior treatment with a PD-1/PD-L1 and/or PI3K inhibitor is allowed unless patient prior treatment was discontinued for intolerance
Exclusion Criteria
	Pregnant or breastfeeding women. NOTE: Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to study registration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. NOTE: Breast milk cannot be stored for future use while the mother is being treated on study
	Diagnosis of follicular grade 3b, post-transplant lymphoproliferative disorder (PTLD), or presence of histologic transformation
	Subjects with LFT abnormalities at baseline (above values per inclusion criteria), history of cirrhotic liver morphology or alcoholic cirrhosis, subjects who use acetaminophen at doses in excess of 2 g every day and have evidence of compromised hepatic reserve
	Primary or metastatic CNS disease prior to study enrollment
	Uncontrolled current illness, including, but not limited to ongoing or active infections, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, evidence of interstitial lung disease or active, noninfectious pneumonitis including symptomatic and/or pneumonitis requiring treatment and/or psychiatric illness or social situations that would limit compliance with study requirements
	History of inflammatory bowel disease i.e. Crohn's disease, ulcerative colitis
	HIV infection. NOTE: HIV testing is required
	Active infection with Hepatitis B or C virus (defined as a positive Hepatitis B surface antigen/ positive Hepatitis C antibody or detectable viral load by PCR). Patients with positive antibody but negative viral loads will be eligible for study participation but will require appropriate prophylaxis
	NOTE: Hepatitis B and C testing are required
	Screening rate-corrected (using Friderica's correction) QT interval (QTcF) must not be > 480 msec via a standard 12-lead ECG within 28 days prior to registration
	Concomitant therapy in the last 4 weeks of any of the following: cytotoxic chemotherapy, immunosuppressive agents, other investigational therapies, or chronic use of systemic corticosteroids (doses 10 mg/day prednisone or equivalent are permitted)
	Active or prior documented autoimmune or inflammatory disorders within the past 3 years prior to study registration. The following are exceptions to this criterion
	Subjects with vitiligo or alopecia
	Subjects with hypothyroidism (eg. following Hashimoto syndrome) stable on hormone replacement or psoriasis not requiring systemic treatment
	Known allergy or reaction to any component of either study drug formulation
	Prior allogeneic stem cell transplant
	Receipt of live attenuated vaccine within 30 days before the first dose of study treatment
	HbA1c > 8.5% at Screening
	Patient that require treatment with agents that are CYP3A4 inhibitors or strong CYP3A4 inducers. Patients who are on agents that fall into this category must be off for at least two weeks prior to start of treatment

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

immunosuppressive agents

hepatitis b surface antigen

marginal zone lymphoma

cirrhosis

pd-l1

cytotoxic chemotherapy

investigational treatment

hepatitis c

interstitial lung disease

autologous stem cell transplantation

alcoholic cirrhosis

pi3k inhibitor

12 lead electrocardiogram

thyroiditis

central nervous system disease

ulcerative

autologous hematopoietic stem cell transplant

symptomatic congestive heart failure

hair thinning

hashimoto syndrome

malt

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor Copanlisib Given in Combination With the Immunotherapeutic Agents Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma